All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Hematologic Oncology Field Sees Almost 20 FDA Approvals in 2024

February 11th 2025

The movement of CAR T-cell therapy to earlier lines of therapy was among many notable advancements greenlit by the FDA in the hematologic space in 2024.

Neoadjuvant Atezolizumab/Trastuzumab/Pertuzumab Is Effective and Safe in HER2+ Early Breast Cancer

February 10th 2025

Neoadjuvant atezolizumab plus trastuzumab, pertuzumab, and abbreviated epirubicin generated pCRs in patients with early HER2-positive breast cancer.

Alisertib Plus Ibrutinib and Rituximab Shows Preclinical Efficacy in MCL Models

February 10th 2025

Alisertib plus ibrutinib and rituximab showed antitumor activity in mantle cell lymphoma in a preclinical study.

Venetoclax Plus Obinutuzumab Improves MRD Clearance in Previously Untreated CLL

February 10th 2025

Venetoclax plus obinutuzumab led to higher undetectable minimal residual disease rates in previously untreated chronic lymphocytic leukemia.

Cancer Vaccine Shows Promise for Patients With Stage III and IV Kidney Cancer

February 10th 2025

Patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma generated successful responses after a personalized cancer vaccine.

Liso-Cel Generates Responses in R/R Marginal Zone Lymphoma

February 10th 2025

Lisocabtagene maraleucel elicited a statistically significant overall response rate in adult patients with relapsed/refractory MZL.

FDA Grants Fast Track Designation to Amezalpat for Hepatocellular Carcinoma

February 10th 2025

The FDA has granted fast track designation to amezalpat for patients with hepatocellular carcinoma.

Bladder Cancer Care Shifts as BCG Shortage Lingers, With Investigative Combinations and Tools at the Forefront

February 10th 2025

Vikram M. Narayan, MD, details updates in the bladder cancer field, including effects of the BCG shortage and upcoming therapies/tools of interest.

Acalabrutinib Plus Venetoclax/Obinutuzumab Demonstrates Efficacy, Safety in Mantle Cell Lymphoma

February 10th 2025

Acalabrutinib plus venetoclax and obinutuzumab demonstrated antitumor activity with a manageable safety profile in mantle cell lymphoma.

Experts Comment on the GI/GU Cancer FDA Approvals From 2024

February 10th 2025

Experts provide insights on the 2024 FDA approvals in the gastrointestinal and genitourinary fields in this list featuring all the regulatory decisions.

Five Under 5: Top Oncology Videos for the Week of 2/2

February 9th 2025

The top 5 videos of the week cover insights in lung cancer, multiple myeloma, breast cancer, and follicular lymphoma.

Pembrolizumab Provides Clinical Benefit in Previously Treated Advanced Clear Cell Gynecologic Cancer

February 9th 2025

Pembrolizumab warrants further evaluation in patients with previously treated advanced clear cell gynecologic cancer in a randomized clinical trial.

The OncFive: Top Oncology Articles for the Week of 2/2

February 8th 2025

Encorafenib combination boosts survival in BRAF V600E+ mCRC, pertuzumab biosimilar BLA is under review for HER2+ breast cancer, and more from OncLive.

Cabozantinib Plus Nivolumab Demonstrates Disease Control in Refractory MSS mCRC

February 8th 2025

The combination of cabozantinib and nivolumab showed 16-week disease control in microsatellite stable colorectal cancer.

Pola-R-CHP Generates Long-Term PFS and DFS Advantages vs R-CHOP in Untreated DLBCL

February 7th 2025

Polatuzumab vedotin plus R-CHP improved PFS and DFS vs R-CHOP at 5 years in previously untreated patients with diffuse large B-cell lymphoma.

Advanced Breast Cancer at Diagnosis Linked to 10% Higher CVD Risk

February 7th 2025

Kevin T. Nead, MD, MPhil, details findings on the association between prevalent CVD and breast cancer and next steps for investigating the connection.

First- and Later-Line Avapritinib Prolongs OS, DOT in Advanced Systemic Mastocytosis

February 7th 2025

Patients with systemic mastocytosis experienced superior OS and DOT outcomes with first- and later-line avapritinib vs midostaurin and BAT, respectively.

FDA Grants Breakthrough Device Designation to Serial CTRS AI Model for NSCLC

February 7th 2025

The FDA has granted breakthrough device designation to Serial CTRS for risk prognosis in non–small cell lung cancer.

MD Anderson Study Resumes With Seclidemstat/Azacitidine in MDS/CMML

February 7th 2025

The combination of seclidemstat and azacitidine will resume study in a phase 1/2 trial in patients with MDS and CMML following a partial clinical hold.

Northwestern Medicine Performs the Highest Number of Lung Transplants in the United States

February 7th 2025

The Canning Thoracic Institute became the highest-volume lung transplant center in the US and achieved the shortest wait time for a lung transplant.